CORCEPT THERAPEUTICS INCORPORATED
CORTLoading price...
Overview
Previous Close94.19
Open95.00
Ask100.42
Bid87.40
Day's Range91.54 - 96.60
52 Week Range28.66 - 97.63
PE Ratio(TTM)265.57
Market Cap9.98B
Volume1.5M
Avg. Volume1.16M
12 Months Earnings47.34M
12 Months Revenue769.10M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 769.10M | 761.41M | 716.08M | 675.04M | 482.38M | 401.86M |
| Cost of Revenue | 13.46M | 12.98M | 11.66M | 10.88M | 6.48M | 5.38M |
| Gross Profit | 755.64M | 748.43M | 704.42M | 664.16M | 475.89M | 396.47M |
| Operating Expenses | 763.86M | 703.63M | 602.47M | 527.21M | 368.61M | 283.84M |
| Profit after Tax (Net Income) | 47.34M | 99.65M | 133.66M | 141.21M | 106.14M | 101.42M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Redwood City, United States
Website: https://www.corcept.com
Co-Founder, President, CEO & Director: Dr. Joseph K. Belanoff M.D.
Employees: 730
About Company:
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.